Formulation of antiretroviral nanocrystals and development into a microneedle delivery system for potential treatment of HIV-associated neurocognitive disorder (HAND)

Marco Abbate, Inken K. Ramöller, Akmal H. Sabri, Alejandro J. Paredes, Aaron Hutton, Peter E. McKenna, Ke Peng, Jessica A. Hollett, Helen McCarthy, Ryan F. Donnelly

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)

Abstract

HIV/AIDS remains a major global public health issue. While antiretroviral therapy is effective at reducing the viral load in the blood, up to 50% of those with HIV suffer from some degree of HIV-associated neurocognitive disorder, due to the presence of the blood–brain barrier restricting drugs from crossing into the central nervous system and treating the viral reservoir there. One way to circumvent this is the nose-to-brain pathway. This pathway can also be accessed via a facial intradermal injection. Certain parameters can increase delivery via this route, including using nanoparticles with a positive zeta potential and an effective diameter of 200 nm or less. Microneedle arrays offer a minimally invasive, pain-free alternative to traditional hypodermic injections. This study shows the formulation of nanocrystals of both rilpivirine (RPV) and cabotegravir, followed by incorporation into separate microneedle delivery systems for application to either side of the face. Following an in vivo study in rats, delivery to the brain was seen for both drugs. For RPV, a Cmax was seen at 21 days of 619.17 ± 73.32 ng/g, above that of recognised plasma IC90 levels, and potentially therapeutically relevant levels were maintained for 28 days. For CAB, a Cmax was seen at 28 days of 478.31 ± 320.86 ng/g, and while below recognised 4IC90 levels, does indicate that therapeutically relevant levels could be achieved by manipulating final microaaray patch size in humans.


Original languageEnglish
Article number123005
Pages (from-to)1-15
Number of pages15
JournalInternational journal of pharmaceutics
Volume640
Early online date2 May 2023
DOIs
Publication statusPublished (in print/issue) - 10 Jun 2023

Data Access Statement

Data will be made available on request.

Keywords

  • Microneedle
  • Rilpivrine
  • Cabotegravir
  • HIV-associated neurocognitive disorder
  • HAND
  • Blood-brain barrier
  • Nanocrystal

Fingerprint

Dive into the research topics of 'Formulation of antiretroviral nanocrystals and development into a microneedle delivery system for potential treatment of HIV-associated neurocognitive disorder (HAND)'. Together they form a unique fingerprint.

Cite this